Brief: Curevac Q3 Pre-Tax Loss Of EUR 47.7 Million

CureVac NV

16/11/2022 12:34

Nov 16 (Reuters) - CureVac NV  5CV.DE :
    * EQS-NEWS: CUREVAC ANNOUNCES FINANCIAL RESULTS FOR THE
THIRD
QUARTER AND FIRST NINE MONTHS OF 2022 AND PROVIDES BUSINESS
UPDATE
    * CUREVAC NV - PHASE 1 STUDIES IN INFLUENZA AND COVID-19 ON
TRACK
TO DELIVER CLINICAL DATA IN Q1 2023
    * CUREVAC NV - TWO PROOF-OF-PRINCIPLE STUDIES PLANNED IN
2023 TO
VALIDATE AND OPTIMIZE SECOND-GENERATION MRNA BACKBONE IN
ONCOLOGY
    * CUREVAC NV - PHASE 1 EXPANSION STUDY OF NON-CODING
RNA-BASED
CANDIDATE CV8102 CONFIRMS SAFETY AND STRONG IMMUNO-MODULATORY
CHARACTERISTICS
    * CUREVAC NV - REVENUES AMOUNTED TO EUR 11.2 MILLION AND EUR
55.7
MILLION FOR THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022
    * CUREVAC NV - OPERATING LOSS AMOUNTED TO EUR 52.4 MILLION
AND EUR
127.9 MILLION FOR THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022
    * CUREVAC NV - PRE-TAX LOSS WAS EUR 47.7 MILLION AND EUR
120.4
MILLION FOR THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022

Source text for Eikon:  ID:nEQ57gsXBa 
Further company coverage:  5CV.DE 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))